adult patients, >/=18 years of age

locally advanced or metastatic (stage iii/iv) non-small cell lung cancer with egfr mutations

measurable disease according to recist criteria

ecog performance status 0-2

adequate haematological, renal and liver function

previous chemotherapy or therapy against egfr for metastatic disease

history of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis

symptomatic cerebral metastases

pre-existing parenchymal lung disease such as pulmonary fibrosis

concomitant use of coumarins